The National Academy of Inventors has honored four academic inventors in Houston with their annual professional distinction. Photos courtesy

Four professors from the University of Houston and University of Texas MD Anderson Cancer Center have been admitted as fellows to the National Academy of Inventors.

From UH, Vincent Donnelly, Moores professor of Chemical and Biomolecular Engineering, and Christine Ehlig-Economides, Hugh Roy and Lillie Cranz Cullen Distinguished university chair of Petroleum Engineering, received the Fellows honor, which is the highest professional distinction awarded to academic inventors.

UH now has 39 professors who are either Fellows or Senior Members of the NAI. Donnelly and Ehlig-Economides will be inducted as NAI fellows at the NAI 13th annual meeting on June 18 in Raleigh, North Carolina.

“The remarkable contributions of the two new NAI Fellows from the University of Houston have left a lasting imprint, earning them high esteem in their respective fields,” Ramanan Krishnamoorti, vice president for research and technology at UH, says in a statement. “Their work stands as a testament to the extraordinary impact inventors can have, reflecting a standard of excellence that truly sets them apart.”

Donnelly, who is considered a pioneer in plasma science with applications to microelectronics and nanotechnology, was elevated to Fellow for his research on complex plasma systems used in the making of microchips. Ehlig-Economides was elevated to NAI fellow for her vital research leading to innovative solutions in the energy and industrial fields. Ehlig-Economides was also the first woman in the United States to earn a doctorate degree in petroleum engineering.

Two other Houston instructors from the University of Texas MD Anderson Cancer Center will be inducted to the program in the new year. Jeffrey H. Siewerdsen, professor within the department of Imaging Physics and the Division of Diagnostic Imaging, and Anil Sood, professor and vice chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA.

Some other notable Texas honorees among the 2024 appointees include:

  • Mark Benden, Texas A&M University
  • Arumugam Manthiram, the University of Texas at Austin
  • Werner Kuhr, Texas Tech University
  • Balakrishna Haridas, Texas A&M University
  • P.Reddy, Texas Tech University Health Sciences Center

“This year’s class of NAI Fellows showcases the caliber of researchers that are found within the innovation ecosystem. Each of these individuals are making significant contributions to both science and society through their work,” Dr. Paul R. Sanberg, president of the NAI, says in the release. “This new class, in conjunction with our existing Fellows, are creating innovations that are driving crucial advancements across a variety of disciplines and are stimulating the global and national economy in immeasurable ways as they move these technologies from lab to marketplace.

UH also ranks 60th on the National Academy of Inventors’ list of the top 100 universities for utility patents granted last year in the U.S. In 2022, UH received 32 utility patents. The university explains that utility patents are among the world’s most valuable assets because they give inventors exclusive commercial rights for producing and using their technology.

The Texas Medical Center's Innovation Institute named 15 Texas companies to its new cancer-focused accelerator program. Photo courtesy of TMCx

TMC cancer therapeutic accelerator names inaugural cohort

cancer innovation

The Texas Medical Center named 15 groundbreaking researchers and companies to its inaugural class of the Accelerator for Cancer Therapeutics on Thursday. All hail from the Lone Star State.

The ACT program is the only accelerator focused on cancer treatment at the earliest stages of commercialization, thanks to a $5 million grant from the Cancer Prevention and Research Institute of Texas awarded to the TMC in the fall of 2019.

The nine-month program kicked-off at the end of January and will be run by TMC Innovation, according to a release from the TMC. It aims to provide the class with resources to help their oncology biotech projects reach new milestones, including even commercialization.

The inaugural cohort is made up of companies and researchers exploring immunotherapy, cell therapy, targeted therapy, cancer pain, and drug platforms. The group is split about evenly between companies and academic researchers. The group of Texans includes:

  • Raptamer Discovery Group
  • IDA Therapeutics
  • Elbrus Therapeutics
  • Parthenon Therapeutics
  • Lokesh Battula
  • Aumeta
  • Autoimmunity Biologic Solutions
  • Max Mamonkin
  • Qing Yi
  • Astero Alta
  • TEZCAT Laboratories
  • Anil Sood
  • Coactigon
  • Xiadong Cheng
  • IonTx

At the end of the nine months, the class will present an integrated strategic plan and at least one grant submission. They will also have the opportunity to pitch investors and corporations.

The class will also gain support in grant writing, chemistry, and funding opportunities, as well as mentorship.

"As the past year has shown, the pace of scientific discovery can be blistering," says Tom Luby, director of TMC Innovation. "At the same time, successfully translating research into effective therapies available to patients requires a mix of business, technical and regulatory skills that may not typically be available to researchers.

"By linking the participants with mentors who can both advance their scientific work and support the technical needs, we expect this first class of ACT participants will make a meaningful difference for cancer patients in Texas and beyond."

TMCx, which is also run by TMC Innovation, recently announced seven health tech companies that were selected to its 2021 class of its health tech accelerator.

Broader in scope that the ACT accelerator, the TMCx startups focus on an array of subject matters from heart health to artificial intelligence to extremity rehabilitation.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.